Docs likely to be 'cautious' when prescribing GSK's first-in-class anemia drug Jesduvroq, survey finds

The path to approval was long and winding for a new class of medicines called hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors. And even after GSK clinched regulatory victory earlier this month, its Jesduvroq may have a hard time swaying doctors in the real world, according to a Spherix Global Insights poll.